REPORT FROM THE 2009 AAN ANNUAL MEETING – Fingolimod (FTY720), a novel sphingosine 1-phosphate receptor modulator, appears to be effective in patients with relapsing-remitting MS, according to the results from a new phase III trial.
Read More
Neurology
Predicting depression in early Parkinsons disease
June 9, 2009REPORT FROM THE 2009 AAN ANNUAL MEETING – An analysis of patients in the DATATOP (Deprenyl and tocopherol antioxidative therapy of parkinsonism) trial (Shoulson I. Acta Neurol Scand Suppl 1989;126:171-175) has attempted to identify factors predictive of depression onset (Uc et al. AAN 2009; abstract S23.004).
Read More
Benefit of breastfeeding in MS
June 9, 2009REPORT FROM THE 2009 AAN ANNUAL MEETING – A small study has found that breastfeeding may protect against MS relapses in the postpartum period, calling into question the wisdom of advising women to resume disease-modifying therapy (DMT) immediately after childbirth and forego breastfeeding.
Read More
Bilingualism: no protective effect
May 20, 2009REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY – An analysis of data from the longitudinal Einstein Aging Study (EAS) has found that bilingualism does not protect against or delay the onset of dementia or amnestic mild cognitive impairment (MCI) (Saunders et al. AAN 2009; abstract S02.004).
Read More
Phase III trial results for cladribine: the CLARITY study
May 20, 2009REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY – Oral cladribine appears to be effective in reducing relapse rates and disability progression, according to the preliminary results from the phase III CLARITY (Cladribine tablets treating MS orally) trial (Giovannoni et al. AAN 2009; abstract LBS.001).
Read More